GLP-1 Story Continues Here are the key figures since Q2 2024: Q2 2024: GLP-1 revenue: $12 million Total revenue: $325 million Share of GLP-1 revenue: 4 % Q3 2024: GLP-1 revenue: $55 million* Total revenue: $441 million Share of GLP-1 revenue: 12 % Q4 2024: GLP-1 revenue: $162 million* Total revenue: $488 million Share of GLP-1 revenue: 33 % Q1 2025: GLP-1 revenue: $ 230 million Total revenue: $596 million Share of GLP-1 revenue: 39 % Q2 2025: GLP-1 revenue: $190 million Total revenue: $545 million Share of GLP-1 revenue: 35 % * Estimate based on the $229M GLP-1 revenue for FY 2024 Revenue Momentum Stalls Amid GLP-1 Reliance Historically Hims has issued conservative guidance and then surpassed the top end of its range
YuanXWangJYangSGaoMCaoLLiXet al
Summary: There is no direct pharmacological interaction between Mounjaro (tirzepatide) and escitalopram, as they work through different mechanisms and metabolic pathways
This guide covers the clinical landscape of compounded dermatology medicationscommon formulations, quality considerations, and how digital prescribing tools are making dermatology compounding more accessible
What dosages is Soliqua available in
Aprile M, Cataldi S, Perfetto C, Federico A, Ciccodicola A, Costa V
